Dr. Reynolds is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Nicolls Rd
Boston, MA 11794Phone+1 617-726-2862
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
- Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
- University of Missouri-Columbia School of MedicineClass of 2008
Certifications & Licensure
- MA State Medical License 2011 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.Cho-Han Chiang, Junmin Song, Kuan-Yu Chi, Yu-Cheng Chang, Nutchapon Xanthavanij
European Journal of Cancer. 2025-02-05 - Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors.Ahmad Rajeh, Katie Roster, Kerry L Reynolds, Nicole R LeBoeuf, Ryan J Sullivan
Journal of the European Academy of Dermatology and Venereology. 2024-12-20 - It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management.Maysa Vilbert, Leyre Zubiri, Meghan J Mooradian, Kerry L Reynolds
JCO Oncology Practice. 2024-12-19
Journal Articles
- Cost-Effectiveness of Pembrolizumab plus Axitinib vs Nivolumab plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the USKerry (Massman) Reynolds, MD, JAMA Network Open
Lectures
- Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trend...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
- Researchers Shed Light on Why Cancer Immunotherapies Sometimes Harm HeartNovember 8th, 2024
- Mechanisms Behind Myocarditis in Cancer Patients Treated with Immune Checkpoint Inhibitors FoundNovember 6th, 2024
- Study Reveals How Cancer Immunotherapy Leads to Deadly Form of Heart Inflammation in Some PatientsNovember 6th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: